eXoZymes has appointed Damien Perriman as Chief Commercial Officer (CCO) in a newly created role. eXoZymes specializes in AI-engineered enzymes that convert sustainable feedstock into essential chemicals, medicines, and biofuels.
Perriman brings over 20 years of experience in commercializing biotechnologies across various markets. His expertise includes nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Prior to joining eXoZymes, he held significant commercial roles at Genomatica and Gevo. He also served as Chairman of the Board for Cellugy, a Danish biotechnology startup.
“eXoZymes represents a new generation of synthetic biology design and scale-up,” Perriman said. He highlighted the company’s potential to set new standards for development speed and product opportunities. Perriman noted that their innovative approach overcomes the limitations of conventional technologies, enabling projects to reach commercial scale more quickly and with lower capital risk.
Michael Heltzen, CEO of eXoZymes, expressed enthusiasm for Perriman’s appointment. “He represents formidable talent and diverse capabilities,” Heltzen said. He added that Perriman’s hiring aligns with the company’s focus on scaling and commercializing biosolutions.
Heltzen emphasized the importance of collaboration with upcoming partners across multiple sectors. With Perriman on board, eXoZymes aims to drive sustainable and competitive product development in the biomanufacturing industry. The company looks forward to a future enriched by innovative solutions and impactful biotechnologies.
